People impacted
Computation chunks
Earn SXOR instantly
Alzheimer's affects 55 million people globally and is projected to triple by 2050. The first disease-modifying drugs were approved in 2023–2024, proving the amyloid cascade can be targeted — but better, earlier, and safer treatments are urgently needed. Distributed simulation maps the amyloid-beta and tau protein interactions in unprecedented detail, guiding next-generation drug design. Supported by Alzheimer's Research UK and MIT Aging Lab.